WASHINGTON, D.C. — January 5, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the Board of Trustees unanimously appointed Axel Hoos, M.D., Ph.D., to serve as chairman of the board, and Peter L. Thoren to serve as vice chairman. Both were appointed to interim positions in December 2014.

Dr. Hoos is senior vice president of Oncology research and development at GlaxoSmithKline (GSK), where he is responsible for the Oncology Therapy Area and building GSK’s immuno-oncology portfolio. Mr. Thoren is executive vice president of Access Industries, Inc., a privately held, U.S.-based industrial group with strategic investments throughout the world.

"Over the past year, Dr. Hoos and Mr. Thoren have provided invaluable guidance in the growth of Sabin and advancing our mission to reduce suffering from vaccine-preventable and neglected tropical diseases," said Ambassador Michael W. Marine, chief executive officer of Sabin. "Their insights and expertise will be especially critical this year, as we complete the search for a new CEO to lead the organization when I retire in a few months and embark on the next phase of Sabin’s development as a global health leader."

Dr. Hoos has been a member of Sabin’s Board of Trustees since 2006.  Mr. Thoren, who also chairs Sabin’s finance committee, has served on the board since 2009.

"In 2015, Sabin reached a number of important milestones, including hosting inaugural conferences supporting dengue vaccine development and the International Association of Immunization Managers; launching a successful public awareness campaign on lymphatic filariasis in India; and helping Uganda advance legislation to take greater ownership of immunization financing," said Dr. Hoos. "This year presents many exciting opportunities as well for Sabin and I look forward to working with the team to achieve even greater impact."


About the Sabin Vaccine Institute

The Sabin Vaccine Institute (Sabin) is a non-profit, 501(c)(3) organization of scientists, researchers and advocates dedicated to reducing needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs). Since its founding in 1993 in honor of Dr. Albert B. Sabin, the developer of the oral polio vaccine, Sabin has been at the forefront of global efforts to eliminate, prevent and cure infectious and neglected tropical diseases.

Sabin develops new vaccines, advocates for increased use of existing vaccines and promotes expanded access to affordable medical treatments in collaboration with governments, academic institutions, scientists, medical professionals and other non-profit organizations. For more information please visit www.sabin.org.

Media Contact
Kelly Toves
+1 (202) 621-1691